Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Sanofi in agreement with Janssen to develop E. coli the vaccine candidate
information fournie par Reuters 03/10/2023 à 07:44

Le logo de Sanofi à Lyon

Le logo de Sanofi à Lyon

PARIS (Reuters) - Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.

Under the terms of the deal, both parties will co-fund current and future research and development costs. Sanofi will pay $175 million upfront to Janssen, followed by development and commercial milestones.

(Reporting by Tassilo Hummel; Editing by Benoit Van Overstraeten)

Valeurs associées

JOHNSON&JOHNSON
228,340 USD NYSE -2,46%
SANOFI
73,340 EUR Euronext Paris -2,06%
© 2026 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.

1 commentaire

  • 03 octobre 09:06

    On est en FRANCE, Ecrivez en Français !!

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
79,24 +0,74%
2CRSI
25,4 -43,05%
SPACEX
185 -3,56%
CAC 40
8 467,98 +0,44%
Or
4 193,31 -0,40%
Chargement...

Pages les plus populaires

L'offre BoursoBank